CURIS INC (CRIS): Entry into a Material Definitive Agreement

CURIS INC (CRIS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Securities Purchase Agreement On October 16, 2026, Curis, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the purchase and

Event · Offering · proposed
Instrument
common stock, pre-funded warrants and common warrants
Gross proceeds
$8.5 million
Shares
16,666,680 shares
Price per share
$0.51 per Share
Use of proceeds
to fund its research and development activities and for working capital and general corporate purposes

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 19, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CRIS
Bearish
high confidence
Mentioned
$CRIS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CRISBearishMed
01

Why it matters

The capital raise funds upcoming trial data, but the issuance of shares and warrants introduces dilution risk.

02

Market read

Primary disclosure of a material definitive agreement; modest raise size limits overall market relevance.

03

What to watch

Placement agents' fees and warrant exercise restrictions may limit immediate dilution impact.

Relevance 6/10Novelty 7/10Timing: closing today (Oct 19, 2026)

Background

Curis Inc. is a clinical‑stage biotech developing therapies for chronic lymphocytic leukemia.

Company-level read

Ticker impact

$CRISBearishHigh confidence
Context

SEC 8‑K reports Curis Inc. entered a securities purchase agreement to sell ~16.7M shares and warrants for $8.5M gross proceeds.

Expected impact

likely downward pressure as market prices in dilution and modest raise size

Evidence & confidence

The raise is small relative to market cap, but adds shares and warrants that can be exercised, increasing supply.

Market effects

May signal continued financing activity in the biotech/clinical‑stage sector.

Limited to U.S. micro‑cap biotech investors.

Low; no broader market effect.

Counterpoint

The raise could be viewed as a vote of confidence, providing needed cash for upcoming CLL trial and potentially supporting upside.

Key entities

  • Curis Inc.

    Biotech firm issuing the securities.

  • Alliance Global Partners

    Lead placement agent for the offering.

Related articles

$CRISHigh

Curis Provides Third Quarter 2026 Business Update

CURIS INC (CRIS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Curis Provides Third Quarter 2026 Business Update Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass., November 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of

$CRISMed

Curis (CRIS) Q3 2026 Earnings Call Transcript

Curis (CRIS) reported Q3 2026 net loss of $8.1M, narrower than 2025. The company is advancing clinical trials for emavusertib in NHL and CLL, with initial data expected by year-end. They aim for accelerated approval submissions in 2027. Cash reserves are $5M, expected to fund operations into 2027.

$CRISMedAI 8/10

Curis Provides Third Quarter 2026 Business Update

Curis, Inc. (CRIS) reported Q3 2026 financial results, showing a net loss of $8.1M, and provided a business update. The company is conducting studies on emavusertib for CLL and PCNSL, with initial data expected in December 2026. Curis completed a public offering and a private placement, extending its cash runway into 2027. Management will host a conference call to discuss the update.

$CRISMedAI 8/10

Curis Prices $5.6 Million Offering Of Shares And Warrants; Stock Up

Curis, Inc. (CRIS) priced a public offering with certain healthcare-focused institutional investors for 3.733 million shares or pre-funded warrants plus warrants. Combined price is $1.50 per share, with expected gross proceeds of about $5.6 million, closing around Aug. 14, 2026. Warrants exercise at $1.75, pre-funded warrants at $0.01. CRIS focuses on Emavusertib (CA-4948).

$CRISMed

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus - Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) reported progress in clinical programs for its oral IRAK4 and FLT3 inhibitor targeting blood cancers. HC Wainwright said TakeAim CLL enrollment is ahead of plan, with year-end guidance raised to 5-10 patients, and reiterated a Buy rating while lifting its price target from $17 to $43. The note also updated emavusertib valuation assumptions and shifted PCNSL launch to 2029 and AML/MDS to 2032.

$CRISMedAI 8/10

Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates - Curis (NASDAQ:C

Curis Inc. (NASDAQ:CRIS) reported updated clinical results for emavusertib and expanded trial timeline guidance. In its TakeAim Primary CNS Lymphoma study, overall response was 100% (5/5) in BTK-naive evaluable patients and 86% (6/7) overall. BTK-experienced response was 26% (10/39). In TakeAim CLL, Curis added sites and raised its year-end data target to 5-10 patients in Dec 2026.